-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 21, 2021, Gao Qiang, Fan Jia, Fudan University, and Zhang Xiaomingduo, Institute of Pasteur, Chinese Academy of Sciences, teamed up to publish a research paper entitled "Spatiotemporal Immune Landscape of Colorectal Liver Metastasis at Single-Cell Level" at Cancer Discovery Online, highlighting effective NAC The beneficial impact of treatment on patients with resectable CRLM and allows for the design of new data-driven treatment combinations, such as NAC plus immunotherapy (click to read)
On March 4, 2022, Fudan University Cai Jiabin, Fan Jia and Chu Yiwei published a research paper entitled "TET2 Inactivation Restrains IL-10-producing Regulatory B cells to Enable Anti-tumor Immunity in Hepatocellular Carcinoma" online in Hepatology.
On February 23, 2022, Fan Jia, Ke Aiwu and Cai Jiabin of Fudan University jointly published a research paper entitled "PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma" in the Journal of Hepatology.
On February 2, 2022, Fuzhou Jian, Huang Xiaowu and Zhou Shaolai jointly published a research paper entitled "Tumor-Derived Exosomes Induce Immunosuppressive Macrophages to Foster Intrahepatic Cholangiocarcinoma Progression" online at Hepatology (IF=17).
On January 26, 2022, Fuzhou Jian and Fan Jia teamed up with Signal Transduction and Targeted Therapy to publish online titled "Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early.
On December 25, 2021, Fudan University Zhou Jian, Fan Jia and Shihe Gene Shaoyang jointly published a research paper entitled "Ultra-Sensitive and Affordable Assay for Early Detection of Primary Liver Cancer Using Plasma cfDNA Fragmentomics" in Hepatology, using a study from 192 Plasma cfDNA samples from PLC patients (159 HCCs, 26 ICCs, 7 cHCC-ICCs) and 170 non-cancer controls (including 53 cirrhosis [LC] or hepatitis B virus [HBV]-positive) were enrolled in the training cohort
Hepatocellular carcinoma (HCC) accounts for nearly 80% of all primary liver malignancies and is the fourth
